Business context and reporting period
InnovAge Holding Corp. provides all-inclusive, capitated care through the Program of All-Inclusive Care for the Elderly (PACE), primarily to frail, dual-eligible seniors. It reported one PACE segment and operated 18 centers in five states, serving approximately 6,850 participants at June 30, 2021.
Period clarification: The supplied filing is the Form 10-K for the fiscal year ended June 30, 2021, with fiscal 2020 comparisons. It does not report a standalone 2020 fourth quarter.
Financial and operating performance
| Metric | FY2021 | FY2020 |
|---|---|---|
| Revenue | $637.8 million | $567.2 million |
| Operating income (loss) | $(12.3) million | $50.9 million |
| Net income (loss) | $(44.7) million | $25.8 million |
| Net income (loss) attributable to InnovAge | $(44.0) million | $26.3 million |
| Operating margin | (1.9)% | 9.0% |
| Net margin | (7.0)% | 4.5% |
| Operating cash flow | $(7.5) million | $43.8 million |
| Investing cash flow | $(19.5) million | $(11.7) million |
| Adjusted EBITDA (non-GAAP) | $85.3 million; 13.4% margin | $65.9 million; 11.7% margin |
Revenue rose 12.4%, driven by higher capitation rates and 6.1% growth in member months. Capitation revenue was $635.3 million, approximately 99.6% of total revenue; Medicaid and Medicare contributed 53% and 47%, respectively. Center-level Contribution Margin increased to $174.1 million, or 27.3% of revenue, from $141.3 million, or 24.9%.
External provider costs increased 13.4% to $309.3 million, reflecting higher cost per participant and more member months. Cost of care, excluding depreciation and amortization, was nearly flat at $154.4 million: lower costs per participant offset census growth. Corporate, general and administrative expense more than doubled to $132.3 million, primarily due to the Apax transaction and IPO-related items. The reported loss also included a $14.5 million debt-extinguishment loss and a $10.9 million gain from consolidating InnovAge Sacramento. Adjusted EBITDA growth should be viewed alongside its substantial adjustments, including $67.6 million of M&A-related items and $18.2 million of contingent-consideration expense.
Liquidity, debt and cash flow
At June 30, 2021, cash and cash equivalents were $201.5 million (restricted cash was an additional $2.2 million). Current assets were $250.9 million and current liabilities were $78.6 million. Operating cash flow was negative $7.5 million, compared with positive $43.8 million in FY2020; capital expenditures were $17.5 million. Cash increased by $89.1 million, largely reflecting financing activity and IPO proceeds.
Debt principal totaled $77.4 million: $75.0 million under the term loan and $2.4 million under a convertible term loan. The $100 million revolving facility had no borrowings at year-end, subject to covenant compliance and other borrowing conditions. The term loan’s stated interest rate was 1.84% at year-end and is variable. Management stated cash and operating cash flows were expected to fund operating and capital needs for at least 12 months. Contractual obligations included $77.4 million of debt principal and $32.5 million of operating lease payments.
Material changes, outlook and key risks
- IPO and financing: The March 2021 IPO generated $370.5 million in net proceeds. Together with new credit-facility proceeds, funds were used to repay prior borrowings, related fees and expenses, and the $20 million NewCourtland acquisition earn-out. The company reported no change in the planned use of IPO proceeds.
- COVID-19: Centers reopened by June 2021 after shifting to home and virtual care. Management said enrollment growth had returned to pre-pandemic levels and reported no COVID-related revenue decline through year-end. The suspension of the 2% Medicare sequestration reduction supported FY2021 revenue; the reduction was scheduled to resume in 2022. COVID-related costs totaled $8.3 million to date, including $4.8 million in FY2021.
- Regulatory and legal matters: CMS notified the company on September 17, 2021 that new enrollment at its Sacramento center was suspended over audit findings related to participant quality of care, pending remediation. Colorado state agencies and CMS had also conducted audits, with final reports expected in early 2022. In July 2021, the Colorado Attorney General issued a civil investigative demand concerning Medicaid billing, patient services and referrals; the outcome was not predictable. The company also disclosed that some centers had not completed certain participant assessments and care plans on time and said it had initiated remediation.
- Principal risks: The company bears full medical-cost risk under capitated contracts and depends heavily on Medicare, Medicaid and a small number of states. Other material risks include reimbursement or risk-adjustment changes, audit recoupments or sanctions, staffing and medical-cost inflation, growth execution, and data security. A third-party ransomware incident involved PHI/PII for over 2,000 current and former participants; regulatory action or claims remained possible.
- Outlook and governance: Management plans to grow through enrollment, center expansion, de novo centers and acquisitions, while continuing investment in technology and the care platform. It expects expenses to rise in absolute terms, including public-company costs. No specific financial guidance was provided. The company does not anticipate dividends in the foreseeable future; principal shareholders controlled approximately 86% of common stock.
Important facts for investors to verify
- Track Sacramento’s enrollment suspension, corrective-action progress, and the final outcomes of the Colorado and other regulatory reviews.
- Assess the Colorado Attorney General investigation, potential exposure, and any related financial or operational consequences.
- Reconcile GAAP losses and negative operating cash flow with Adjusted EBITDA, including the scale and recurrence risk of excluded items.
- Review medical-cost trends, Medicare risk-adjustment documentation, capitation rates, and the impact of the scheduled Medicare sequestration reduction.
- Confirm liquidity, covenant headroom, variable-rate debt exposure, and the cash requirements of planned expansion and lease obligations.